Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial

🏆 Top 10📊 OpenAlex

Most Cited Paper

in Heart Failure Treatment and Management

18 Months Post-Publication

Class of 2026

“Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial”

AuthorsBarry A Borlaug et al.

Barry A. Borlaug

JournalNature Medicine

Mayo Clinic

Citations108

DOI10.1038/s41591-024-03374-z

A research intelligence initiative by Pepkio

pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026/

Topics

tirzepatide · Heart failure with preserved ejection fraction · Heart failure with preserved ejection fraction · Obesity · Glucose-dependent insulinotropic polypeptide receptor · Glucose-dependent insulinotropic polypeptide receptor · GLP-1 receptor agonist · GLP-1 receptor agonist · circulatory volume expansion · pressure overload · cardiovascular-kidney end-organ damage · systolic blood pressure · estimated blood volume · C-reactive protein · Inflammation · Renal function · Urine albumin-creatinine ratio · microalbuminuria · Natriuretic peptides · Natriuretic peptides · troponin T · Cardiovascular death · Acute decompensated heart failure · KCCQ Clinical Summary Score · 6-minute walk distance · Renal function · myocardial injury · SUMMIT trial · Randomized controlled trial

Share on X

Cite this ranking

Pepkio Research Index (PRI). Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026. Accessed 2026-07-13.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459